Table 1.
Medical Condition | Visfatin |
---|---|
Atherosclerosis | Increased serum levels [10,31] Increased expression in instable plaques [31] |
Endothelial dysfunction | Increased serum levels [18] |
Cardioprotection | Reduces infarct area [36] |
Metabolic Syndrome | Controversial, Increased serum levels [34] |
Adiponectin | Controversial [18,27] |
Hepatic Fat Disease | Diminished serum levels in steatohepatitis [16] Increased serum levels with progressive portal inflammation [17] |
Tumoral replication | Visfatin antagonist being tested [19] |
Acute lung injury | Increased serum levels [15] |
Renal insufficiency | Increased serum levels [18] |
Beta cell function impairment | Increased serum levels [10,22,23,28,29] |
Insulin resistance | No correlation [20,22,23] |
Insulin-mimetic effect | Controversial, no effect [5,10,15-20,22-24,27-29] |
Diabetes | Controversial [18,23,27,28] |
Obesity | Increased serum levels [20,22] |
Visceral Fat | Controversial, no correlation [5,15-20,27] |
Vascular smooth muscle | Promotes inflammation [32] |